Dashboard
1
High Debt Company with a Debt to Equity ratio (avg) at times
- Poor long term growth as Operating profit has grown by an annual rate -9.80% of over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
- The company has been able to generate a Return on Equity (avg) of 2.09% signifying low profitability per unit of shareholders funds
2
Poor long term growth as Operating profit has grown by an annual rate -9.80% of over the last 5 years
3
Risky -
Stock DNA
Pharmaceuticals & Biotechnology
SEK 1,224 Million (Small Cap)
31.00
NA
14.21%
0.15
1.99%
0.42
Revenue and Profits:
Net Sales:
865 Million
(Quarterly Results - Jun 2025)
Net Profit:
-15 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
10.13%
0%
10.13%
6 Months
-2.25%
0%
-2.25%
1 Year
6.1%
0%
6.1%
2 Years
6.1%
0%
6.1%
3 Years
2.72%
0%
2.72%
4 Years
-81.47%
0%
-81.47%
5 Years
-87.71%
0%
-87.71%
Midsona AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
1.17%
EBIT Growth (5y)
-9.80%
EBIT to Interest (avg)
1.16
Debt to EBITDA (avg)
3.47
Net Debt to Equity (avg)
0.14
Sales to Capital Employed (avg)
1.02
Tax Ratio
41.54%
Dividend Payout Ratio
61.88%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
2.63%
ROE (avg)
2.09%
Valuation key factors
Factor
Value
P/E Ratio
31
Industry P/E
Price to Book Value
0.39
EV to EBIT
14.44
EV to EBITDA
6.14
EV to Capital Employed
0.47
EV to Sales
0.44
PEG Ratio
0.34
Dividend Yield
15.05%
ROCE (Latest)
3.25%
ROE (Latest)
1.26%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
865.00
918.00
-5.77%
Operating Profit (PBDIT) excl Other Income
42.00
59.00
-28.81%
Interest
11.00
15.00
-26.67%
Exceptional Items
-11.00
0.00
Consolidate Net Profit
-15.00
3.00
-600.00%
Operating Profit Margin (Excl OI)
6.90%
24.00%
-1.71%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is -5.77% vs 2.80% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -600.00% vs 109.38% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
3,727.00
3,793.00
-1.74%
Operating Profit (PBDIT) excl Other Income
281.00
208.00
35.10%
Interest
58.00
74.00
-21.62%
Exceptional Items
0.00
-39.00
100.00%
Consolidate Net Profit
47.00
-53.00
188.68%
Operating Profit Margin (Excl OI)
34.60%
13.40%
2.12%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -1.74% vs -2.72% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 188.68% vs 89.42% in Dec 2023
About Midsona AB 
Midsona AB
Pharmaceuticals & Biotechnology
Midsona AB, formerly Midelfart Sonesson AB is a Sweden-based company engaged in the development, manufacture and marketing of consumer healthcare products in the Nordic region. Its products are divided into three product areas: Healthfoods, Hygiene, Personal Care. The Company consists of three geographical areas, namely Sweden, Norway and Finland. The business areas in Sweden, Norway and Finland market and sell nutritional supplements, herbal remedies, health foods, skin care and beauty products to grocery stores, pharmacies and health stores in respective geographic markets. The Company has several priority brands, such as Friggs, Urtekram, Naturdiet, Miwana, MyggA, Dalblads, Tri Tolonen, Supernature.
Company Coordinates 
Company Details
Dockplatsen 16, Box 21009 , MALMO None : 200 21
Registrar Details






